Dementia drug trial fails during World Alzheimer's Month

26 September 2017 – End stage trials for potential new Alzheimer’s Disease drug Intepirdine have failed to show positive results. Alzheimer’s Disease International (ADI) welcomes more research into new treatments, urging that global investment must continue to enhance prevention, earlier diagnosis and care.

Pharmaceutical company Axovant announced the results of the MINDSET trial during World Alzheimer’s Month, following excitement that it may represent progress towards achieving the first new treatment for dementia since 2002.

Paola Barbarino, CEO of ADI, expressed her disappointment at the results, supporting the message by David Hung, M.D., Chief Executive of Axovant that, “The fight against Alzheimer’s […] is too important to be derailed.”

She said: “The results from this hugely significant trial are saddening for the almost 50 million people who are living with dementia worldwide, and for whom there is no cure.

“ADI continues to call for more research to improve the lives of these individuals and their care partners, and that companies such as Axovant do not give up on dementia. It is critical that research continues to be underpinned by a global effort to improve prevention of dementia earlier in the life course, with more support for diagnosis, access to care and effective support.”

Where next?